tiprankstipranks
Trending News
More News >
Immunovant (IMVT)
NASDAQ:IMVT
US Market
Advertisement

Immunovant (IMVT) Income Statement

Compare
842 Followers

Immunovant Income Statement

Last quarter (Q4 2025), Immunovant's total revenue was $160.00K, a decrease of -89.33% from the same quarter last year. In Q4, Immunovant's net income was $-106.45M. See Immunovant’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Mar 25Mar 24Mar 23Mar 22Mar 21
Total Revenue
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit
$ 0.00$ -231.00K$ -1.32M$ -1.23M$ -998.00K
Operating Expenses
$ 438.15M$ 282.71M$ 208.28M$ 156.03M$ 108.12M
Depreciation and Amortization
$ 0.00$ 231.00K$ 1.32M$ 1.23M$ 998.00K
EBITDA
$ 0.00$ -269.98M$ -209.63M$ -155.58M$ -106.79M
Operating Income
$ -438.15M$ -282.71M$ -198.47M$ -156.16M$ -107.79M
Other Income/Expenses
$ 25.20M$ 23.94M$ -2.67M$ -781.00K$ 328.00K
Pretax Income
$ -412.95M$ -258.77M$ -210.95M$ -156.81M$ -107.79M
Net Income
$ -413.84M$ -259.34M$ -210.96M$ -156.73M$ -107.43M
Per Share Metrics
Basic EPS
$ -2.73$ -1.88$ -1.71$ -1.43$ -1.22
Diluted EPS
$ -2.73$ -1.88$ -1.71$ -1.43$ -1.22
Weighted Average Shares Outstanding
151.57M 138.10M 123.08M 109.68M 87.76M
Weighted Average Shares Outstanding (Diluted)
151.57M 138.10M 123.08M 109.68M 87.76M
Currency in USD

Immunovant Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis